IGF2 as A Drug Target and Biomarker for Obesity and Cancer (G3481)

Target Name: IGF2

NCBI ID: G3481

IGF2

IGF2 as A Drug Target and Biomarker for Obesity and Cancer

Insulin-like growth factor II (IGF2) is a protein that plays a crucial role in the growth and development of tissues, including muscle, bone, and fat cells. It is a key regulator of cell proliferation and differentiation, and is often dysregulated in various diseases, including obesity, type 2 diabetes, and cancer. As a result, IGF2 has become an attractive target for drug development, with various compounds being synthesized and tested for their potential therapeutic effects. In this article, we will explore IGF2 as a drug target and its potential as a biomarker for various diseases.

The IGF2 Signaling Pathway

IGF2 is a member of the insulin-like growth factor II (IGF2) family, which is characterized by the presence of a long N-terminus containing a farnesylated cysteine 鈥嬧?媟esidue and a single transmembrane segment. IGF2 is a 14-kDa protein that is expressed in various tissues, including muscle, bone, heart, and fat cells. It plays a critical role in the growth and development of these tissues, and is often dysregulated in various diseases, including cancer and obesity.

The IGF2 signaling pathway is complex and involves multiple interacting proteins. The most well-studied interaction is between IGF2 and the transcription factor, SMAD. IGF2 can bind to the SMAD receptor and enhance its transcriptional activity, leading to the production of various growth factors, including transforming growth factor beta (TGF-β), which is a key regulator of cell proliferation and differentiation.

SMAD is a transcription factor, which is a protein that plays a critical role in the regulation of gene expression. It consists of a nucleotide-binding domain, a transcription domain, and a C-terminal domain that contains a protein-coding region. SMAD has four isoforms, each with a different amino acid sequence.

IGF2 has been shown to enhance the transcriptional activity of SMAD, leading to the production of TGF-β. TGF-β is a key regulator of cell proliferation and differentiation, and is involved in the development and maintenance of tissues, including muscle, bone, and fat cells. IGF2 has also been shown to regulate the activity of other transcription factors, including nuclear factor of growth (NGT), which is involved in the regulation of cell growth and differentiation.

IGF2 and Cancer

Cancer is a disease that is characterized by the rapid and uncontrolled growth of cells. The IGF2 signaling pathway has been shown to be involved in the regulation of cancer cell growth and survival. IGF2 has been shown to promote the growth and survival of various types of cancer cells, including breast, ovarian, and colorectal cancer.

Research has shown that IGF2 can be used as a potential therapeutic target for cancer, with various compounds being synthesized and tested for their potential therapeutic effects. For example, IGF2 has been shown to inhibit the activity of IGF2 in cancer cells, leading to a reduction in cell growth and survival. IGF2 has also been shown to enhance the sensitivity of cancer cells to chemotherapy, leading to a reduction in the effectiveness of these treatments.

IGF2 and Obesity

Obesity is a disease that is characterized by excess body weight and is a major risk factor for various cardiovascular diseases, including diabetes and cardiovascular disease. The IGF2 signaling pathway has been shown to be involved in the regulation of obesity and body weight. shown to promote the growth and survival of obese cells, leading to an increase in body weight.

Research has shown that IGF2 can be used as a potential therapeutic target for obesity, with various compounds being synthesized and tested for their potential therapeutic effects

Protein Name: Insulin Like Growth Factor 2

Functions: The insulin-like growth factors possess growth-promoting activity (By similarity). Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF2 is influenced by placental lactogen. Also involved in tissue differentiation. In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver (Probable). Acts as a ligand for integrin which is required for IGF2 signaling (PubMed:28873464). Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation (By similarity). Inhibits myoblast differentiation and modulates metabolism via increasing the mitochondrial respiration rate (By similarity)

The "IGF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets